Patient demographics and treatment variables
| . | Capped dose . | Uncapped dose . | P . |
|---|---|---|---|
| Patients, n | 454 | 2392 | |
| Male sex, n (%) | 309 (68) | 1641 (69) | .826 |
| Age, mean ± SD, y | 56.8 ± 15.8 | 54.8 ± 15 | .011 |
| Body weight, mean ± SD, kg | 106.9 ± 8.6 | 111.3 ± 13.5 | <.001 |
| Body height (n = 2010), mean ± SD, cm | 173 ± 9.9 | 173 ± 10 | <.987 |
| Body mass index (n = 2010), mean ± SD | 36 ± 5.1 | 38 ± 6.1 | <.001 |
| Body mass index >30 (n = 2010), n (%) | 320 (93) | 1581 (95) | .241 |
| VTE risk factor, n (%) | |||
| Recent immobility ≥4 d | 74 (16) | 430 (18) | .421 |
| Recent surgery | 42 (9.3) | 255 (11) | .403 |
| Active cancer | 83 (18) | 279 (12) | <.001 |
| Metastatic cancer | 31 (6.8) | 105 (4.4) | .571 |
| Estrogen use | 26 (5.7) | 115 (4.8) | .409 |
| Pregnancy or postpartum | 2 (0.44) | 18 (0.75) | .758 |
| None of the above (unprovoked) | 272 (60) | 1,462 (61) | .637 |
| Prior VTE | 88 (19) | 386 (16) | .099 |
| Underlying disease, n (%) | |||
| Major bleeding in the past month | 5 (1.1) | 16 (0.67) | .363 |
| Chronic lung disease | 54 (12) | 295 (12) | .876 |
| Chronic heart failure | 21 (4.6) | 119 (5.0) | .814 |
| Anemia | 102 (22) | 505 (21) | .532 |
| Platelet count <100 × 103/µL | 8 (1.8) | 34 (1.4) | .528 |
| Creatinine clearance level <60 mL/min | 22 (4.8) | 96 (4.0) | .440 |
| Creatinine clearance level <30 mL/min | 2 (0.44) | 10 (0.42) | >.99 |
| Initial VTE presentation, n (%) | |||
| Deep vein thrombosis | 252 (56) | 939 (39) | <.001 |
| Upper limb DVT | 20 (4.4) | 62 (2.6) | .045 |
| Lower limb proximal DVT | 191 (42) | 746 (31) | <.001 |
| Lower limb distal DVT | 37 (8.1) | 124 (5.2) | .015 |
| Pulmonary embolism, n (%) | 124 (27) | 949 (40) | <.001 |
| DVT and PE, n (%) | 78 (17) | 504 (21) | .066 |
| . | Capped dose . | Uncapped dose . | P . |
|---|---|---|---|
| Patients, n | 454 | 2392 | |
| Male sex, n (%) | 309 (68) | 1641 (69) | .826 |
| Age, mean ± SD, y | 56.8 ± 15.8 | 54.8 ± 15 | .011 |
| Body weight, mean ± SD, kg | 106.9 ± 8.6 | 111.3 ± 13.5 | <.001 |
| Body height (n = 2010), mean ± SD, cm | 173 ± 9.9 | 173 ± 10 | <.987 |
| Body mass index (n = 2010), mean ± SD | 36 ± 5.1 | 38 ± 6.1 | <.001 |
| Body mass index >30 (n = 2010), n (%) | 320 (93) | 1581 (95) | .241 |
| VTE risk factor, n (%) | |||
| Recent immobility ≥4 d | 74 (16) | 430 (18) | .421 |
| Recent surgery | 42 (9.3) | 255 (11) | .403 |
| Active cancer | 83 (18) | 279 (12) | <.001 |
| Metastatic cancer | 31 (6.8) | 105 (4.4) | .571 |
| Estrogen use | 26 (5.7) | 115 (4.8) | .409 |
| Pregnancy or postpartum | 2 (0.44) | 18 (0.75) | .758 |
| None of the above (unprovoked) | 272 (60) | 1,462 (61) | .637 |
| Prior VTE | 88 (19) | 386 (16) | .099 |
| Underlying disease, n (%) | |||
| Major bleeding in the past month | 5 (1.1) | 16 (0.67) | .363 |
| Chronic lung disease | 54 (12) | 295 (12) | .876 |
| Chronic heart failure | 21 (4.6) | 119 (5.0) | .814 |
| Anemia | 102 (22) | 505 (21) | .532 |
| Platelet count <100 × 103/µL | 8 (1.8) | 34 (1.4) | .528 |
| Creatinine clearance level <60 mL/min | 22 (4.8) | 96 (4.0) | .440 |
| Creatinine clearance level <30 mL/min | 2 (0.44) | 10 (0.42) | >.99 |
| Initial VTE presentation, n (%) | |||
| Deep vein thrombosis | 252 (56) | 939 (39) | <.001 |
| Upper limb DVT | 20 (4.4) | 62 (2.6) | .045 |
| Lower limb proximal DVT | 191 (42) | 746 (31) | <.001 |
| Lower limb distal DVT | 37 (8.1) | 124 (5.2) | .015 |
| Pulmonary embolism, n (%) | 124 (27) | 949 (40) | <.001 |
| DVT and PE, n (%) | 78 (17) | 504 (21) | .066 |
SD, standard deviation.